glp 1 cirrhosis Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) GLP‑1 Liver Disease: New MASLD

Even better outcomes are seen with surgical procedures like the gastric sleeve, which yield up to 5x the weight loss than even the most powerful GLP-1

Schurr JM, Fujimoto BS, Huynh L, Chiu DT (2013)

Injectable BPC-157 at standard dosages of 0.25 mg to 0.5 mg daily appears well-tolerated in community reports, though individual responses vary

investigating the regulatory mechanisms of the gut microbiota in mixed infections and multi-pathogen scenarios to elucidate its immunomodulatory roles in complex infections

Disparities in health condition diagnoses among aging transgender and cisgender Medicare beneficiaries, 20082017